T
here are a number of definitions of multimorbidity (MM) that have been advocated by various groups. [1] [2] [3] [4] [5] [6] Some use comorbidity indexes to study MM, [7] [8] [9] while others define MM as a list of ≥ 1 conditions, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and still others define it as ≥ 2 conditions. 13, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Some are interested in using such definitions to directly influence care, 2, 5, 11, 15, [19] [20] [21] 28, 29, [32] [33] [34] [35] while others are interested in measuring or benchmarking quality of care in these more challenging patients. 2, 5, 7, 9, 10, 12, [16] [17] [18] [23] [24] [25] [26] 30, 36 MM lists utilize various datasets, some dependent on claims data, 7, 22, 23, 33, [37] [38] [39] [40] [41] [42] while others incorporate additional clinical items not generally found in administrative data. 6, 8, 9, 11, 12, 14, 16, 17, 23, 26, 29, [31] [32] [33] 40 In this study, we present a new definition for identifying multimorbid patients in general surgery and develop a list of qualifying comorbidity sets (QCSs) that operationalize that definition. The goal of this project was to develop a list of comorbidity sets that could be used to define a group of patients with MM. Such a list would be preferable to simply defining patients with increased risk through a multivariable model for 2 reasons: first, we believe clinicians want to be able to identify specific patients with MM based on specific reasons for that classification. Knowing that a patient is high risk from a model does not convey the same depth of information as knowing that the patient is high risk with MM because of specific comorbidities. Second, we want to ultimately match these specific comorbidity combinations to aid quality improvement actions for specific types of patients. The list can also inform surgeons of patients that have especially high risk of 30-day mortality when weighing whether to recommend a proposed procedure. Finally, the new methodology and resulting definition that we present herein can be used as a template to develop lists of comorbidity sets for other medical and surgical patients.
METHODS

Conceptual Model and Design
To develop a claims-based list of QCSs that define mutimorbidity, we start with a number of desired properties:
(1) the list should provide an estimate of the increased odds of mortality relative to a general population undergoing that same surgery. In so doing, we want a typical representative population of patients undergoing general surgery to serve as the control group that informs us as to how much the comorbidity set of interest elevates the risk of death above the baseline average; (2) each elevated odds ratio (OR) associated with a comorbidity set must have a statistically definable confidence interval (CI) and P-value. Here we will define this elevated risk as the lower bound of a 95% CI; (3) the list should include the more common comorbidity combinations that represent at least 0.5% of patients in the population, because the list should be practical for use in regression and matching applications and yield adequate data to support refined analyses; (4) the list development process should exclude patients with some conditions that are already high risk or may influence the attempt of caregivers and family to address life-threatening complications. For this analysis, we excluded patients with metastatic solid cancer or dementias, and also excluded patients aged 85 and older for similar reasons. We therefore concentrate on comorbidity combinations that increase risk among patients who lack these excluding characteristics, but would suggest that when utilizing our list, these other categories could be explored depending on the purpose of the application (as will be illustrated).
Patient Population
We were granted access by the Centers for Medicare and Medicaid Services (CMS) Virtual Research Data Center to administrative claims data for older Medicare beneficiaries who were admitted to acute care hospitals in the United States for general surgery in [2009] [2010] [2011] [2012] [2013] . The Virtual Research Data Center hosted each patient's beneficiary summary file (base, chronic conditions, cost and utilization, and other chronic or potentially disabling conditions segments) and administrative claims (inpatient, outpatient, carrier/part B, Hospice, and Home Health Agency files). We leveraged these files for a comprehensive assessment of disease burden in the 12 months before each patient's index hospitalization for general surgery.
Admissions in 2009-2010 were used for the development of comorbidity sets. We applied exclusion steps that would permit complete ascertainment of comorbid conditions in the period before admission. Specifically, we excluded hospitalizations where the patient was under 66 years old at admission, the patient had evidence of hospice care, or the patient lacked complete fee-for-service Medicare in the 12 months before admission, the month of admission, or the month after admission. We also restricted the sample to the 50 US states and the District of Columbia. Finally, if a patient had multiple qualifying admissions for general surgery in 2009-2010, we chose a random one.
To illustrate one use of the newly developed comorbidity sets, in an additional dataset of 2011 admissions, we asked whether multimorbid patients defined as having at least 1 QCS who were admitted to hospitals with Medicare general surgery volume in the upper 10th percentile of hospitals in the United States (a characteristic generally associated with better outcomes 43 ) would have lower 30-day mortality than multimorbid patients admitted to hospitals in the lower third.
Finally, we assessed the replicability of our algorithm by analyzing the same surgical population described above for the additional years 2012 and 2013.
Outcomes
The outcome used to assess risk was all-cause, alllocation mortality within 30 days of admission.
Statistical Methods
Defining QCSs
We developed our methodology using a random 20% sample of unique eligible patients admitted for one of the general surgery procedures listed in Table 1 from 2009 to 2010 (excluding patients with metastatic solid cancer, Alzheimer disease and related disorders, and age 85 or older for this study). This 20% sample was not used in subsequent analyses, which refer to the complementary 80% random sample.
The algorithm for constructing the list of QCSs was as follows:
Step 1: Construct Candidate Sets of Comorbidities. For this study, we considered the 50,183 possible comorbidity combinations that can be formed from 67 candidate comorbidities. Our study team formed the list of 67 comorbidities by taking the union of comorbidities derived from extensive lists of comorbidities from the AHRQ chronic conditions dataset, the AHRQ Elixhauser comorbidities, the Hospital Compare comorbidities, and a list of surgical comorbidities we have used in our previous work (Supplementary Digital Content Section 1, Supplemental Digital Content 1, http://links.lww. com/MLR/B597). We considered all triples of 3 comorbidities, all pairs of 2 comorbidities, and all individual comorbidities. Comorbidities were assigned to patients if they appeared in a 12-month lookback or were present on admission for the index hospitalization. Some related comorbidities were classified into mutually exclusive severity levels. If a patient had both more and less severe manifestations of the same condition, the patient was only classified as having the more severe manifestation. Specifically, "chronic renal failure with dialysis" (CRFD) was defined as mutually exclusive from "renal dysfunction," such that if a patient had a history of CRFD and renal dysfunction in the past year, then the patient was recorded as having CRFD, but not renal dysfunction. Similarly, if a patient had diagnoses for both moderate/severe diabetes and mild diabetes in the past year, the patient was recorded as having moderate/severe diabetes, but not mild diabetes.
Step 2: Cross-screening of comorbidity sets for elevated risk. If 50,183 true null hypotheses are tested at the 0.05 level, it is expected 0.05×50,183 = 2905 of them will be falsely rejected. To avoid identifying 2905 nonsense comorbidity sets by chance, we used the cross-screening methodology of Zhao et al, 44 an alternative to the Bonferroni adjustment, which would require comorbidity sets to be significant at 0.05/50,183. In cross-screening, the data are split in half at random. The first random half suggests a limited number of comorbidity sets to be validated in the second random half. The second random half suggests a limited number of comorbidity sets to be validated in the first random half. The validated comorbidity sets are those that validate in at least one half. Both halves are used to screen, and both halves are used to validate. A validated comorbidity set must look promising in one half and pass a formal statistical test in the other half, so it must pass 2 tests. Because a limited number of comorbidity sets seek validation on the second half, the Bonferroni adjustment used in the validation sample divides by a small fraction of the 50,183 potential hypotheses. For detailed discussion of cross-screening, its properties and limitations, see Zhao et al. 44 Cross-screening strongly controls the family-wise error rate: the chance that it falsely rejects ≥ 1 true null hypotheses is at most 0.05, despite having screened 50,183 combinations of comorbidities. It is very unlikely that even one of our comorbidity sets fails to achieve its stated property of more than double the conditional odds of death relative to the reference population.
Step 3: Specifics of implementing cross-screening. We wanted comorbidity sets that were associated with more than a doubling of the odds of 30-day mortality compared with the general population undergoing the same procedure because a 2-fold increase in the odds of 30-day mortality was clinically important and produced a group of multimorbid patients comprising about a third of eligible patients when tested in our initial 20% sample. This seemed desirable since too large a number would reduce the usefulness of the categorization of MM when focusing on quality improvement, and too few would create sample size problems when examining subgroups. Of note, we excluded patients with evidence of dialysis from the reference group, because from a clinical perspective, this group disproportionately increased the reference group's risk in our initial 20% sample. We used the Mantel-Haenszel test 45 in each random half of the data to screen comorbidity sets that could possibly occur subject to the mutually exclusive severity levels described earlier, and which had a prevalence of at least 0.5%. These requirements yielded 6559 possible combinations. The Mantel-Haenszel test was stratified by the 156 general surgical principal procedures (see Table 1 for details), 2 age groups (66 and above to below 75, 75-85), and a variable describing whether each patient was in the study population or in the reference group. The resulting 2×2×156 table compared 30-day mortality for patients with a given comorbidity set relative to a representative reference population who had varied comorbidity sets or no comorbidity sets, adjusting for the procedure. In the screening stage of cross-screening, a 99.9% CI was formed, and if this interval was completely above 2, this comorbidity set was referred to the second half-sample for validation by a more stringent standard. In cross-screening, if K comorbidity sets were selected by this screening step using the first halfsample, then just these K comorbidity sets were tested using the second half-sample, testing the null hypothesis of an OR ≤ 2 at level 0.05/(2K). Also, if K' comorbidity sets were selected by this screening step using the second half-sample, then just these K' comorbidity sets were tested using the first half-sample, testing the null hypothesis of an OR ≤ 2 at level 0.05/(2K'). Any comorbidity set that validated in either half was included in our list of QCSs. The chance that even 1 comorbidity set with an OR ≤ 2 incorrectly made it onto our list is at most 0.05: with 95% CI, every QCS on our list has an OR > 2 relative to the reference group. All statistical tests were completed using SAS version 9.4. 46 
The 2011 Matching Application Study
We explored how patients with our new definition of MM fared at hospitals in the upper decile of general surgery volume relative to the lower third. Hospital volumes were calculated using all available Medicare inpatient bills. Index admissions for matching were screened for data quality in the same manner as was carried out for 2009 and 2010, and if a patient had multiple general surgery admissions in 2011, a random admission was chosen.
In this analysis, we matched "focal" patients treated at low-volume hospitals to controls treated at high-volume hospitals. We matched exactly for International Classification of Diseases, Ninth Revision principal procedure and MM (yes, no) as defined by our newly developed list. Within exact groups, specific QCSs defining MM were balanced using a refined balance technique 47 between the low and high-volume groups; age categories, sex, race, admission type, and individual comorbidities were also included in the balance hierarchy. Other matching variables included a propensity score for admission to a low-volume hospital, 48 and a risk score for 30-day mortality (on admission), derived from a model constructed on the initial 20% development data from 2009 to 2010 (see Supplementary Digital Content Section 2, Supplemental Digital Content 1, http://links.lww.com/MLR/ B597, for the model details). We also minimized the total Mahalanobis distance between cases and controls on the matching covariates. Refined balance was implemented using the NETFLOW procedure in SAS, 46 but is available more directly in the R package rcbalance. 49 Matches were considered balanced if all covariates had standardized differences below 0.2 after matching. Differences in 30-day mortality between matched pairs were tested using the McNemar statistic. 50 
RESULTS
In Table 2 we describe the 80% sample development dataset (2009) (2010) ) and the 2011 application dataset. The The development dataset represents the 80% random sample of 2009-2010 patients used in the split-sample cross-screening design. The Application dataset represents the additional dataset used to calculate out-of-sample point estimates and 95% confidence intervals for the qualifying comorbidity sets. Both datasets exclude patients aged 85 and older, those with metastatic solid tumors, and Alzheimer disease and related disorders.
ADHD indicates attention deficit hyperactivity disorder; AIDS, acquired immune deficiency syndrome; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; HTN, hypertension; TIA, transient ischemic attack. There were 576 QCSs that met our statistical criteria in the development dataset (2009) (2010) , and of these, a parsimonious set of 113 is displayed. This list of 113 QCSs includes all sets of singles (2), doubles (33) , and triples (78) without duplicating any set whose components are already on the list as singles or doubles. When applied to a 2011 out-of-sample dataset of 170,575 patients, the multimorbidity definition identified 61,772 unique patients (36.21%). The displayed odds ratios are computed from this same 2011 dataset. The 2 reference groups are a 20% random sample of 2011 patients (excluding 589 CRFD patients), and a second reference group representing only patients that did not have 1 of the 576 QCSs. Note, these data exclude any patients age 85 or older, or with a history of dementia or metastatic solid cancer. We examine the odds of mortality for this final group at the bottom of the table.
*A crosswalk between abbreviated and nonabbreviated versions of comorbidity names is available in Supplementary Digital Content Section 1 (Supplemental Digital Content 1, http://links.lww.com/MLR/B597). † Rates for the comorbidity sets reflect the percentage of the study population after exclusions (N = 170,575). Rates for the excluded patients reflect the percentage of the total 2011 general surgical population before exclusions (N = 254,190) .
AMI indicates acute myocardial infarction; Arr emerg, arrhythmia emergency; Arr nonemerg, arrhythmia nonemergency; COPD, chronic obstructive pulmonary disease; CRFD, chronic renal failure on dialysis; diab mod, diabetes moderate; dys, dysfunction; fib, fibrillation; HTN, hypertension; isch, ischemic; pulm circ, pulmonary circulation; PVD, peripheral vascular disease; QCS, qualifying comorbidity set; TIA, transient ischemic attack. sample sizes were large, and both populations looked very similar in terms of age, sex, and comorbidities.
We provide the parsimonious list of the final validated QCSs in Table 3 . There were 576 comorbidity sets that validated in our cross-screening algorithm, and we created the parsimonious list of 113 by first including the singles (2), then the doubles not covered by the singles (33) , and then triples not covered by singles or doubles (78). The parsimonious list identifies all multimorbid patients, but would not describe all specific QCSs (see Supplementary Digital Content Section 3, Supplemental Digital Content 1, http://links.lww.com/MLR/ B597, for a complete list of all 576 validated QCSs, and Sections 4 and 5, Supplemental Digital Content 1, http://links.lww. com/MLR/B597, for the details of the development of the lists). Some important observations can be made. First, 2 comorbidities each provided a strong signal that such a patient had more than double the odds of dying compared with the reference group. These were a history of chronic renal failure on dialysis (CRFD) and a history of "Emergency Arrhythmia." Ultimately, our algorithm selected only 25 of the initial 67 candidate comorbidities as elements of the nonduplicative list of 113 QCSs (see Supplementary Digital Content Section 6, Supplemental Digital Content 1, http://links.lww.com/MLR/B597, for a description of these 25 comorbidities, and their association with other comorbidities that constitute the QCSs). Table 3 provides sample sizes, ORs, and 95% CIs estimated from the 2011 application dataset, for each of the 113 parsimonious QCSs that were derived in the 2009-2010 dataset. The Mantel-Haenszel ORs use 2 different reference groups. The second-to-last column reports the odds of mortality versus a representative reference group comprising 2011 patients, who had no QCSs or varied QCSs, whereas the last column uses all nonmultimorbid patients as a reference group. Table 3 also provides the group results for all multimorbid patients. As can be seen, multimorbid patients as a group had a 1.90 odds of mortality (95% CI, 1.77-2.04) versus a general reference population, and a 3.72 odds of mortality (95% CI, 3.51-3.94) versus the nonmultimorbid group. At the bottom, we also report the ORs associated with each excluded population using the same 2 reference populations as above. For excluded patients, the overall increased odds of mortality versus the general reference group was 2.05 (1.91-2.20), and the odds of mortality versus nonmultimorbid patients was 3.83 (3.60-4.07). Examining individual excluded subgroups, all displayed significant increases in mortality relative to the reference group, with age 85 and above displaying the greatest risk.
It is important to understand that there were many patients who had multiple QCSs, and, as expected, patients with more QCSs generally had higher mortality rates (Supplementary Digital Content Section 7, Supplemental Digital Content 1, http://links. lww.com/MLR/B597). In Supplementary Digital Content 7c (Supplemental Digital Content 1, http://links.lww.com/MLR/ B597), we demonstrate that nonmultimorbid patients only began to have comparable risk to multimorbid patients when they had ≥ 9 of the comorbidities used to define the QCSs.
External Matching Application Using QCSs
To demonstrate that our newly developed QCSs can be applied to a matching study, we matched patients across high-volume hospitals and low-volume hospitals. Table 4 describes the quality of the match for multimorbid patients. All standardized differences after matching were ≤ 0.10. For complete matching tables, see Supplementary Digital Content Section 8 (Supplementary Digital Content 1, http://links.lww. com/MLR/B597). Patients had higher 30-day mortality at lowvolume hospitals, displaying an OR of 1.46 (95% CI, 1.21-1.75), P < 0.0001 versus high-volume hospitals. In 3151 matched pairs with MM, the odds of mortality at low-volume hospitals compared to high-volume hospitals was 1.36 (95% CI, 1.09-1.70) (P = 0.006). In 6387 pairs without MM, the OR was even higher, 1.67 (95% CI, 1.21-2.30) (P = 0.0016). In matched multimorbid patients, the death rate at low-volume hospitals was 6.7% versus 5.2% in high-volume hospitals; in the nonmultimorbid group, the death rate was 1.7% in low-volume hospitals versus 1.0% in high-volume hospitals. In Figure 1 we provide Kaplan-Meier survival plots for the multimorbid and nonmultimorbid matched pairs at the high-volume and lowvolume hospitals. Although we developed our multimorbid definition for 30-day mortality (a common measure of surgical quality), we extend the plot to 1-year mortality to better observe the longer-term follow-up of these vulnerable patients.
Further Validation Studies
To assess the stability of our algorithm for defining MM, we obtained the 2012 and 2013 surgical patient dataset and reran the cross-screening algorithm. 
Comparison of Multimorbidity Definitions
Finally, we asked if our new definition of MM provides different information from a well-known existing approach (though one not specifically developed for our eligible general surgery patients). We compared our definitions to those developed by Salive, 24 which defined multimorbid patients as having ≥ 2 comorbidities from a list of 15. Using the 2011 dataset, and applying our same study exclusions, we compared the present study's definition of MM to the Salive definition (see Supplementary Digital Content Section 10, Supplemental Digital Content 1, http://links. lww.com/MLR/B597, for a comparison of the MM classifications). Among 170,575 patients, the concordance was only 47%. When our definition called a patient multimorbid and the Salive definition did not (N = 1061), the mortality rate was 4.5%. When our definition suggested no MM and Salive suggested there was MM (N = 89,077), the mortality rate was 1.7%.
DISCUSSION
MM is a difficult concept to define and, understandably, variations in definitions of MM are common. We wanted our definitions of QCSs to be relevant to inpatient general surgical care, so we based our algorithm on the outcome of 30-day all-cause mortality and we excluded patients 85 or older, metastatic solid cancer patients, and patients with dementia to focus our definition on other, less obvious, reasons for poor outcomes. Of interest, these categories of exclusion had comparable risks to our defined multimorbid patients as a whole. Users of our MM definitions can, if desired, add back these high-risk groups, as such groups had comparable elevated risk to our defined MM group having at least 1 QCS. We further required our approach to rigorously define what an important elevation of risk would be for a patient defined as having a QCS. Hence, we wanted a simultaneous 95% CI for the OR associated with any specific QCS to be above a doubling of the odds of death relative to a defined reference population. We defined comorbidity sets with singles, doubles, and triples, but did not explore quartets or beyond because the number of possibilities would be too large and the data too thin.
The advantage of defining MM through QCSs, rather than using a risk score to define elevated risk, is that the reasons for being considered high risk can be determined through the QCS designations. Although any given risk score can be achieved by a vast number of comorbidity combinations, patients designated as having MM are defined by their QCSs. Hospitals can determine whether outcomes vary by specific QCSs or groups of QCSs to improve quality of care.
Our resulting definition of MM, the presence of at least 1 QCS, performed very well on our 2011 application dataset. We found that as a group, patients categorized as multimorbid had a much higher risk of death than a general reference population or those without MM. To further study our definition, and to demonstrate that we can perform matching studies leveraging the 113 parsimonious comorbidity sets, we asked whether surgical patients with MM fared better at highvolume hospitals, as high volume is often associated with better outcomes. 43 We found that matching quality was excellent, and we observed significantly elevated mortality at low-volume hospitals. We further replicated our crossscreening algorithm using 2012-2013 patients, and found above 93% concordance with our original definition when we classified out-of-sample 2011 patients. Where there was discordance in defining a patient with MM, the development dataset that included more secondary diagnoses (2012-2013) identified more patients as multimorbid. As datasets and coding systems change over time, users of these algorithms will need to update MM definitions accordingly.
There are important limitations to our study. The development of MM definitions is somewhat dependent on the dataset utilized (as shown above), though we did find good stability across the claims data we had access to. In the future, more clinical data may become available and care patterns may change, requiring algorithms to be re-run. Any approach that uses claims data may result in some misclassification of the severity of comorbidities. Our decision to use the more severe state in the comorbidity diabetes and renal failure may have overestimated the severity of these conditions for some patients. Furthermore, there is always the possibility that lack of uniformity in coding may occur, with some hospitals upcoding patients to show a greater number of multimorbid patients.
In summary, our study has developed and validated a new definition of MM based on a methodology that ensures each QCS has elevated odds of 30-day mortality with high confidence and provides elevated group-wise risk as well. Our hope is that this new approach will aid caregivers treating multimorbid patients and aid policymakers evaluating care for these very complex and vulnerable patients.
